Reportlinker Adds Drug-Eluting Stents – Global Market Opportunities

NEW YORK, Nov. 18 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Drug-Eluting Stents – Global Market Opportunities

http://www.reportlinker.com/p0164240/Drug-Eluting-Stents—Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage are key factors driving growth of drug-eluting stents. Development of innovative treatment methods and preventive measures for coronary diseases, obesity, and diabetes are few factors influencing the long-term growth prospects of the drug-eluting stents market.

Through registering significant growth in the recent past, incidents of adverse effects such as in-stent thrombosis is expected to significantly restrict future market growth. In-stent thrombosis is a common long-term adverse effect of DES where patients develop clots. Although in-stent thrombosis cases occur rarely, they are highly fatal. On the contrary, bare-metal stents do not pose such threats thereby augmenting its usage in interventional management. The rise in in-stent thrombosis cases paves the way for anti-thrombotic therapies. Moreover, drug-eluting stents faces stiff competition from advanced and safer technologies such as tiny wire mesh tubes.

These and other market data and trends are presented in “Drug-Eluting Stents: Global Market Opportunities” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

DRUG-ELUTING STENTS BMR-1040

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. MARKET OVERVIEW 4

Current and Future Analysis 4

Major Issues and Trends 5

Drug-Eluting Stents Transforming the Scenario of

Interventional- Cardiology Market 5

Adverse Effects Restrict Market Growth 5

Innovation and Development Drive Market Growth 6

High Price of DES – A Major Impediment to Rapid Development 6

Potential Decline in Hospital Revenues 6

Glaring Lack of Health-Related Initiatives World Over 7

Bioabsorbable Stents Closer to Reality Than Expected 7

3. PRODUCT FACTS 8

Major Drug-Eluting Stent Products in the Market 8

4. COMPETITIVE SCENARIO 9

Drug-Eluting Stents-Competitive Arena 9

Market Dominated by Small Band of Players 10

Cordis (A Johnson & Johnson Company) 10

Cypher Leads the Drug-Eluting Stent Market 10

Boston Scientific 10

Taxus Beats Cypher in the US 10

5. REGULATORY ENVIRONMENT 11

FDA Framework 11

FDA to Monitor Drug-Eluting Stents 11

Issues Raised by FDA Regarding the Safety of Stent 11

6. CORPORATE DEVELOPMENTS 11

MIV Therapeutics Acquires Biosync Scientific 11

J & J Acquires Conor Medsystems 12

Lombard Collaborates With S&N 12

India Establishes Asia’s first Catheter and Stent Unit 12

Abbott Requests FDA Approval for Xience 12

Brookwood and TTV Start Joint Venture 12

SurModics Acquires Brookwood Pharmaceuticals, Inc 13

ARIAD Collaborates with ICON Medical 13

Biosensors Acquires 50% Stake in JWMS 13

Boston Completes European and Intercontinental Enrollment Phases 14

FDA Approves Boston Scientifis’s Taxus Stent with Extended

Shelf Life 14

Abbott Launches Drug-Eluting Coronary Stent 14

Boston Introduces Taxus(R) Express2(TM) in Japan 14

7. MAJOR PLAYERS 15

Abbott Vascular (USA) 15

Angiotech Pharmaceuticals, Inc (Canada) 15

AngioDynamics® Inc. (USA) 15

Boston Scientific, Inc. (USA) 15

Boston Scientific Cardiac Rhythm Management (USA) 16

Biocompatibles International Plc (UK) 16

Biosensors International Pte Ltd. (Singapore) 16

Cordis Corporation (USA) 16

Implant Sciences Corporation (USA) 17

Medtronic, Inc. (USA) 17

MIV Therapeutics Inc (Canada) 17

SurModics, Inc. (USA) 17

8. GLOBAL MARKET ANALYTICS 18

9. THE UNITED STATES 19

Issues and Trends 19

US Healthcare Ideology 19

The Important Role of Medicaid in the US 19

Drug-Eluting Stents-Competitive Arena 20

Leading DES Products in the Market 20

Cypher – First to Market 20

Taxus Beats Cypher 20

Regulatory Environment 20

FDA Framework 20

Issues Raised by FDA Regarding the Safety of Stent 21

10. JAPAN 21

Healthcare System in Japan 21

11. EUROPE 23

a. France 25

b. Germany 25

c. Italy 26

d. The United Kingdom 27

e. Spain 27

f. Rest of Europe 28

12. REST OF WORLD 29

EXHIBITS

Table 1: Percentage Breakdown of Leading Drug Eluting Stents

Brands in the World-2006

Table 2: Percentage Breakdown of Leading Players in the Global

Drug Eluting Stents Market -2008

Table 3: Global Drug-Eluting Stents Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 4: Percentage Breakdown of Global Drug-Eluting Stents

Market by Region for the Years 2008 & 2012

Table 5: Percentage Breakdown of Major Players in the US

Market for Drug Eluting Stents – 2008

Table 6: Drug-Eluting Stents Market in the US: 2007-2015

(Sales in US$ Million)

Table 7: Percentage Breakdown of Major Players in the Japanese

Market for Drug Eluting Stents -2008

Table 8: Drug-Eluting Stents Market in Japan: 2007-2015 (Sales

in US$ Million)

Table 9: Percentage Breakdown of Major Players in the European

Market for Drug Eluting Stents -2008

Table 10: Drug-Eluting Stents Market by Region in Europe:

2007-2015 (Sales in US$ Million)

Table 11: Percentage Breakdown of Drug-Eluting Stents Market

by Region in Europe for the Years 2008 & 2012

Table 12: Drug-Eluting Stents Market in France: 2007-2015

(Sales in US$ Million)

Table 13: Drug-Eluting Stents Market in Germany: 2007-2015

(Sales in US$ Million)

Table 14: Drug-Eluting Stents Market in Italy: 2007-2015

(Sales in US$ Million)

Table 15: Drug-Eluting Stents Market in the UK: 2007-2015

(Sales in US$ Million)

Table 16: Drug-Eluting Stents Market in Spain: 2007-2015

(Sales in US$ Million)

Table 17: Drug-Eluting Stents Market in Rest of Europe:

2007-2015 (Sales in US$ Million)

Table 18: Drug-Eluting Stents Market in Rest of World:

2007-2015 (Sales in US$ Million)

COMPANIES PROFILED

To order this report:

Drug-Eluting Stents – Global Market Opportunities

http://www.reportlinker.com/p0164240/Drug-Eluting-Stents—Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker